Angiocrine Bioscience Inc., of New York, licensed the rights to a technology developed by researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College, led by Shahin Rafii, a company founder, director of the Institute and professor of medicine, genetic medicine and reproductive medicine at Weill Cornell.